Results from the International Consensus Conference on Myo-inositol and d -chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS

Abstract In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d -chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ov...

Full description

Saved in:
Bibliographic Details
Published in:European Journal of Obstetrics & Gynecology and Reproductive Biology 2015-12, Vol.195, p.72-76
Main Authors: Facchinetti, Fabio, Bizzarri, Mariano, Benvenga, Salvatore, D’Anna, Rosario, Lanzone, Antonio, Soulage, Christophe, Di Renzo, Gian Carlo, Hod, Moshe, Cavalli, Pietro, Chiu, Tony T, Kamenov, Zdravko A, Bevilacqua, Arturo, Carlomagno, Gianfranco, Gerli, Sandro, Oliva, Mario Montanino, Devroey, Paul
Format: Article
Language:English
Subjects:
Congenital Abnormalities - metabolism
d-Chiro-inositol
Diabetes, Gestational - metabolism
Epimerase activity
Female
Gestational diabetes mellitus
Humans
Inositol - metabolism
Inositol - therapeutic use
Insulin Resistance
Life Sciences
Metabolic syndrome
Metabolic Syndrome - metabolism
Myo-inositol
Obstetrics and Gynecology
Polycystic ovary syndrome
Polycystic Ovary Syndrome - drug therapy
Polycystic Ovary Syndrome - metabolism
Pregnancy
Stereoisomerism
Vitamin B Complex - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d -chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome. Although these molecules have different functions, very often their roles have been confused, while the meaning of several observations still needs to be interpreted under a more rigorous physiological framework. With the aim of clarifying this issue, the 2013 International Consensus Conference on MI and DCI in Obstetrics and Gynecology identified opinion leaders in all fields related to this area of research. They examined seminal experimental papers and randomized clinical trials reporting the role and the use of inositol(s) in clinical practice. The main topics were the relation between inositol(s) and metabolic syndrome, polycystic ovary syndrome (with a focus on both metabolic and reproductive aspects), congenital anomalies, gestational diabetes. Clinical trials demonstrated that inositol(s) supplementation could fruitfully affect different pathophysiological aspects of disorders pertaining Obstetrics and Gynecology. The treatment of PCOS women as well as the prevention of GDM seem those clinical conditions which take more advantages from MI supplementation, when used at a dose of 2 g twice/day. The clinical experience with MI is largely superior to the one with DCI. However, the existence of tissue-specific ratios, namely in the ovary, has prompted researchers to recently develop a treatment based on both molecules in the proportion of 40 (MI) to 1 (DCI).
ISSN:0301-2115
1872-7654
2590-1613
DOI:10.1016/j.ejogrb.2015.09.024